The past few years have brought a wave of promising new targets for the treatment of cancer and inflammatory diseases. Monoclonal antibodies have emerged as highly specific biologics, increasingly recognized as the gold standard across multiple therapeutic areas. <\/p>\n\n\n\n
At Immune Biosolutions, we have immunized B-cell libraries for a variety of targets that enable fast and efficient discovery pipelines, accelerating the path from target to therapeutic candidate. <\/p>\n\n\n\n
In addition, our team has built strong expertise in bi-specific antibody engineering, allowing us to synergize signaling pathway modulation and unlock greater therapeutic potential. Here\u2019s a few targets of interest: <\/p>\n\n\n\n
PD-1 and PD-L1<\/strong> <\/p>\n\n\n\n The Programmed cell death protein 1 (PD-1, CD279) and its ligand programmed death-ligand 1 (PD-L1, CD274) have become cornerstone targets in immuno-oncology. Many cancer cells exploit this receptor\u2013ligand interaction to suppress immune surveillance and escape recognition by T cells. By blocking the PD-1\/PD-L1 pathway, therapies can reinvigorate antitumor immunity, an approach that has already transformed cancer treatment and continues to expand into new indications. <\/p>\n\n\n\n CCR8<\/strong> <\/p>\n\n\n\n C-C chemokine receptor type 8 (CCR8) has emerged as an attractive immuno-oncology target because of its selective and high expression on tumor-resident regulatory T cells (Tregs). Monoclonal antibodies are the modality of choice for this pathway, offering both high specificity and the ability to induce antibody-dependent cellular cytotoxicity (ADCC). By simultaneously depleting immunosuppressive Tregs and activating effector responses through ADCC, CCR8-directed therapies aim to remodel the tumor microenvironment into a pro-inflammatory, anti-tumor state. <\/p>\n\n\n\n TGF-\u03b2<\/strong> <\/p>\n\n\n\n Transforming Growth Factor Beta (TGF-\u03b2) is an attractive therapeutic target because of its involvement in a wide range of biological pathways. However, this pleiotropy also makes it a challenging node to drug, where balance and specificity are critical to maximize efficacy while minimizing off-target effects. Among available modalities, recombinant antibodies remain the most compelling due to their high specificity and long half-life. In particular, bi-specific antibody formats are emerging as powerful tools for fine-tune signaling modulation and to achieve more precise therapeutic outcomes. <\/p>\n\n\n\n IL-1\u03b2<\/strong><\/p>\n\n\n\n Interleukin-1 Beta (IL-1\u03b2) is a pleiotropic cytokine with a central role in diverse inflammatory and tumor-promoting pathways. While this broad activity makes it an attractive target, it also demands careful modulation to avoid unwanted immunosuppression. Bi-specific antibody engineering offers a promising strategy to narrow targeting toward disease-driving contexts, improving selectivity and maximizing therapeutic benefit.\u00a0<\/p>\n\n\n\n For a complete list of available pre-immunized libraries, contact us<\/a> or visit our website<\/a>. <\/p>\n","protected":false},"excerpt":{"rendered":" The past few years have brought a wave of promising new targets for the treatment of cancer and inflammatory diseases….<\/p>\n","protected":false},"author":35,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_kad_blocks_custom_css":"","_kad_blocks_head_custom_js":"","_kad_blocks_body_custom_js":"","_kad_blocks_footer_custom_js":"","_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","footnotes":""},"categories":[55],"tags":[],"class_list":["post-4018","post","type-post","status-publish","format-standard","hentry","category-article"],"acf":[],"taxonomy_info":{"category":[{"value":55,"label":"Article"}]},"featured_image_src_large":false,"author_info":{"display_name":"Laurence Tessier","author_link":"https:\/\/immunebiosolutions.com\/en\/author\/ltessieribiosolutions-com\/"},"comment_info":0,"category_info":[{"term_id":55,"name":"Article","slug":"article","term_group":0,"term_taxonomy_id":55,"taxonomy":"category","description":"","parent":0,"count":2,"filter":"raw","cat_ID":55,"category_count":2,"category_description":"","cat_name":"Article","category_nicename":"article","category_parent":0}],"tag_info":false,"_links":{"self":[{"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/posts\/4018","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/comments?post=4018"}],"version-history":[{"count":3,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/posts\/4018\/revisions"}],"predecessor-version":[{"id":4025,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/posts\/4018\/revisions\/4025"}],"wp:attachment":[{"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/media?parent=4018"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/categories?post=4018"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/immunebiosolutions.com\/en\/wp-json\/wp\/v2\/tags?post=4018"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}